The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s ...
Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off on the stock.
Note to readers: The Daily Edition will not be published Dec. 23 through Jan. 1. Look for it again in your inbox on Jan. 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback